Outputs (2)

Impact of SARS-CoV-2 spike antibody positivity on infection and hospitalisation rates in immunosuppressed populations during the omicron period: the MELODY study (2025)
Journal Article
Mumford, L., Hogg, R., Taylor, A., Lanyon, P., Bythell, M., McPhail, S., Chilcot, J., Powter, G., Cooke, G., Ward, H., Thomas, H., McAdoo, S. P., Lightstone, L., Lim, S. H., Pettigrew, G. J., Pearce, F. A., & Willicombe, M. (2025). Impact of SARS-CoV-2 spike antibody positivity on infection and hospitalisation rates in immunosuppressed populations during the omicron period: the MELODY study. Lancet, 405(10475), 314-328. https://doi.org/10.1016/S0140-6736%2824%2902560-1

Background
In the UK, booster COVID-19 vaccinations have been recommended biannually to people considered immune vulnerable. We investigated, at a population level, whether the absence of detectable anti-SARS-CoV-2 spike protein IgG antibody (anti-S... Read More about Impact of SARS-CoV-2 spike antibody positivity on infection and hospitalisation rates in immunosuppressed populations during the omicron period: the MELODY study.

Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY (2023)
Journal Article
Pearce, F. A., Lim, S. H., Bythell, M., Lanyon, P., Hogg, R., Taylor, A., Powter, G., Cooke, G. S., Ward, H., Chilcot, J., Thomas, H., Mumford, L., McAdoo, S. P., Pettigrew, G. J., Lightstone, L., & Willicombe, M. (2023). Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY. The Lancet Rheumatology, 5(8), E461-E473. https://doi.org/10.1016/S2665-9913%2823%2900160-1

Background:
In the UK, additional COVID-19 vaccine booster doses and treatments are offered to people who are immunosuppressed to protect against severe COVID-19, but how best to choose the individuals that receive these vaccine booster doses and t... Read More about Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY.